Cleo Diagnostics Ltd (COV) - Net Assets
Based on the latest financial reports, Cleo Diagnostics Ltd (COV) has net assets worth AU$8.83 Million AUD (≈ $6.24 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$9.96 Million ≈ $7.05 Million USD) and total liabilities (AU$1.14 Million ≈ $803.21K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cleo Diagnostics Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$8.83 Million |
| % of Total Assets | 88.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cleo Diagnostics Ltd - Net Assets Trend (2022–2025)
This chart illustrates how Cleo Diagnostics Ltd's net assets have evolved over time, based on quarterly financial data. See Cleo Diagnostics Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cleo Diagnostics Ltd (2022–2025)
The table below shows the annual net assets of Cleo Diagnostics Ltd from 2022 to 2025. For live valuation and market cap data, see Cleo Diagnostics Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.83 Million ≈ $4.13 Million |
-37.88% |
| 2024-06-30 | AU$9.39 Million ≈ $6.65 Million |
+1095.54% |
| 2023-06-30 | AU$-943.41K ≈ $-667.52K |
-2131.34% |
| 2022-06-30 | AU$-42.28K ≈ $-29.92K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cleo Diagnostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 782986000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$13.71 Million | 234.93% |
| Total Equity | AU$5.83 Million | 100.00% |
Cleo Diagnostics Ltd Competitors by Market Cap
The table below lists competitors of Cleo Diagnostics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
K Auction Inc.
KQ:102370
|
$47.46 Million |
|
Allegiant Gold Ltd
V:AUAU
|
$47.48 Million |
|
Take Solutions Limited
NSE:TAKE
|
$47.49 Million |
|
Hexza Corporation Bhd
KLSE:3298
|
$47.49 Million |
|
True North Copper Ltd
AU:TNC
|
$47.44 Million |
|
Plutus Financial Group Limited Ordinary Shares
NASDAQ:PLUT
|
$47.43 Million |
|
Penguen Gida Sanayi AS
IS:PENGD
|
$47.43 Million |
|
Mercer International Inc
F:AEZ
|
$47.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cleo Diagnostics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,392,030 to 5,834,440, a change of -3,557,590 (-37.9%).
- Net loss of 3,999,130 reduced equity.
- Other factors increased equity by 441,540.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.00 Million | -68.54% |
| Other Changes | AU$441.54K | +7.57% |
| Total Change | AU$- | -37.88% |
Book Value vs Market Value Analysis
This analysis compares Cleo Diagnostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | AU$0.00 | AU$0.49 | x |
| 2023-06-30 | AU$-0.01 | AU$0.49 | x |
| 2024-06-30 | AU$0.07 | AU$0.49 | x |
| 2025-06-30 | AU$0.05 | AU$0.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cleo Diagnostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -337.55%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.19x
- Recent ROE (-68.54%) is below the historical average (-27.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-39.70K |
| 2023 | 0.00% | -1571.13% | 0.10x | 0.00x | AU$-1.64 Million |
| 2024 | -40.03% | -626.38% | 0.06x | 1.05x | AU$-4.70 Million |
| 2025 | -68.54% | -337.55% | 0.17x | 1.19x | AU$-4.58 Million |
Industry Comparison
This section compares Cleo Diagnostics Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $194,539,512
- Average return on equity (ROE) among peers: -192.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cleo Diagnostics Ltd (COV) | AU$8.83 Million | 0.00% | 0.13x | $47.45 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.84 Billion |
| Adherium Ltd (ADR) | $830.00K | -1420.96% | 1.70x | $7.60 Million |
| Aroa Biosurgery Ltd (ARX) | $53.69 Million | -32.84% | 0.36x | $154.57 Million |
| Atomo Diagnostics Ltd (AT1) | $6.98 Million | -71.26% | 0.33x | $12.75 Million |
| Avita Medical Inc (AVH) | $16.23 Million | 0.00% | 0.05x | $119.77 Million |
| Anteris Technologies Global Corp (AVR) | $5.01 Million | 0.00% | 0.01x | $848.00 Million |
| Control Bionics Ltd (CBL) | $6.27 Million | -94.35% | 0.44x | $26.53 Million |
| Cardiex Ltd (CDX) | $3.28 Million | -81.11% | 0.41x | $13.23 Million |
| Compumedics Ltd (CMP) | $11.68 Million | -158.94% | 1.04x | $35.62 Million |
| Cochlear Ltd (COH) | $1.84 Billion | 19.39% | 0.49x | $5.47 Billion |
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more